semaglutide and bone loss (Ozempic) linked to fewer fractures despite greater weight Worried About Bone Loss on

On average, persons taking semaglutide or tirzepatide therapy in this study discontinued these medications after about 6 to 8 months, Ostrominski said

Other observed adverse events in trials have included upper respiratory tract infections, urinary tract infections, and gallbladder-related effects (which are a known class effect of GLP-1 receptor agonists)

doi: 10.1111/jdi.12956

Weight comes off

There have also been a number of studies examining impacts on addiction in real-world use of the drugs prescribed for other diseases, as well as countless anecdotes of peoples personal experiences

doi: 10.1172/jci.insight.86351